Fidelity Investments’s BioNTech BNTX Stock Holding History

Fidelity Investments’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$705M	Buy	7,571,805 +1,862,565	+33%	+$175M	0.03%	431
2026 Q1	$507M	Sell	5,709,240 -224,354	-4%	-$23.1M	0.03%	506
2025 Q4	$565M	Buy	5,933,594 +480,114	+9%	+$48.4M	0.03%	464
2025 Q3	$538M	Sell	5,453,480 -2,705,531	-33%	-$289M	0.03%	466
2025 Q2	$869M	Buy	8,159,011 +875,600	+12%	+$88.4M	0.05%	314
2025 Q1	$663M	Sell	7,283,411 -418,065	-5%	-$46.8M	0.04%	357
2024 Q4	$878M	Buy	7,701,476 +1,401,547	+22%	+$160M	0.05%	294
2024 Q3	$748M	Buy	6,299,929 +5,598,190	+798%	+$515M	0.05%	348
2024 Q2	$56.4M	Sell	701,739 -132,651	-16%	-$12.1M	﹤0.01%	1271
2024 Q1	$77M	Buy	834,390 +697,426	+509%	+$66.9M	0.01%	1161
2023 Q4	$14.5M	Sell	136,964 -100,880	-42%	-$10.2M	﹤0.01%	1724
2023 Q3	$25.8M	Buy	237,844 +10,422	+5%	+$1.15M	﹤0.01%	1488
2023 Q2	$24.5M	Sell	227,422 -722	-0.3%	-$81.2K	﹤0.01%	1564
2023 Q1	$28.4M	Buy	228,144 +45,592	+25%	+$6.26M	﹤0.01%	1476
2022 Q4	$27.4M	Sell	182,552 -81,803	-31%	-$12.6M	﹤0.01%	1493
2022 Q3	$35.7M	Sell	264,355 -159,412	-38%	-$24.4M	﹤0.01%	1378
2022 Q2	$63.2M	Sell	423,767 -828,309	-66%	-$127M	0.01%	1161
2022 Q1	$214M	Buy	1,252,076 +923,552	+281%	+$155M	0.02%	740
2021 Q4	$84.7M	Sell	328,524 -1,445,165	-81%	-$396M	0.01%	1185
2021 Q3	$484M	Sell	1,773,689 -223,324	-11%	-$71M	0.04%	434
2021 Q2	$447M	Buy	1,997,013 +242,867	+14%	+$45.8M	0.04%	475
2021 Q1	$192M	Sell	1,754,146 -1,144,559	-39%	-$122M	0.02%	806
2020 Q4	$236M	Sell	2,898,705 -1,604,079	-36%	-$157M	0.02%	682
2020 Q3	$312M	Sell	4,502,784 -5,708,030	-56%	-$410M	0.03%	457
2020 Q2	$681M	Buy	10,210,814 +9,472,629	+1,283%	+$473M	0.07%	232
2020 Q1	$43.1M	Sell	738,185 -1,547,034	-68%	-$60.2M	0.01%	1087
2019 Q4	$77.4M	Buy	+2,285,219	New	+$51.2M	0.01%	1020

Other funds holding BNTX

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Fidelity Investments's BNTX Position: Q2 2026 in Review

Fidelity Investments increased its BioNTech (BNTX) stake by 33% in Q2 2026, buying an estimated $175M and bringing the position to 7,571,805 shares worth $705M. The position accounts for 0.03% of the portfolio, ranked #431.

Fidelity Investments first reported a position in BNTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $878M in Q4 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Fidelity Investments held 7,571,805 shares of BioNTech worth $705M as of Q2 2026.
Fidelity Investments bought 1,862,565 BioNTech shares in Q2 2026, an estimated $175M.
BioNTech made up 0.03% of Fidelity Investments's portfolio in Q2 2026, its #431 holding.
Fidelity Investments first reported a position in BioNTech in Q4 2019 and has held it in 27 quarters since.
Fidelity Investments's BioNTech position peaked at $878M in Q4 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.